Lecithin: benefits, dosage, contraindications

Mis à jour le

Lecithin is a mixture of natural lipids made up of more than 50% phospholipids, mainly phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol, and variable amounts of other substances such as triglycerides, fatty acids and carbohydrates, depending on the source. It is found in egg yolk, soy, fish, offal and other plants such as sunflower or canola. Its exact composition depends on the source. For example, egg lecithin contains 69% phosphatidylcholine and 24% phosphatidylethanolamine, while soy lecithin contains 24% phosphatidylcholine, 22% phosphatidylethanolamine and 19% phosphatidylinositol. The fatty acids contained in lecithin are mainly omega-6 fatty acids with a small amount of omega-3 fatty acids. Unlike animal-derived lecithins, phosphatidylserine is present in very low amounts in plant lecithins. Lecithins are excellent emulsifiers, commonly used by the food industry under the code 'E322'. Plant lecithins are important sources of phospholipids and have the ability to increase the bioavailability and incorporation of fatty acids into certain target tissues (brain, liver, muscles, ...). It is already known that marine-derived phospholipids are preferred carriers of n-3 polyunsaturated fatty acids (PUFAs) or omega-3s, compared to triglycerides supplying the same PUFAs. Some studies tend to confirm these properties for plant lecithins, which can serve as carriers of specific fatty acids, such as alpha-linolenic acid (ALA), the main precursor of omega-3s. As supplements, lecithins help to modulate lipid metabolism, increase the bioavailability of the fatty acids they contain and exert lipid-regulating, anti-inflammatory and antioxidant effects.

Other name(s) 

Soy lecithin, sunflower lecithin

Family or group: 

Fatty Acids

Active ingredients:

Phosphatidylserine

Phosphatidylcholine


Indications

Scoring methodology

EFSA approval.

Several randomized, double-blind, controlled clinical trials (> 2), including a significant number of patients (>100), with consistently positive conclusions for the indication.
Several randomized, double-blind, controlled clinical trials (> 2), including a significant number of patients (>100), with positive conclusions for the indication.
One or more randomized studies, or several cohorts or epidemiological studies, with positive conclusions for the indication.
Clinical studies exist but are uncontrolled, with conclusions that may be positive or conflicting.
No clinical studies to date that can demonstrate the indication.


Ulcerative colitis
✪✪✪✪✪

Clinical research suggests that taking slow-release phospholipids rich in phosphatidylcholine improves symptoms and remission rates in patients with ulcerative colitis. Three single-center randomized controlled trials with a lecithin containing 30% phosphatidylcholine yielded positive results, whereas a trial with a lecithin containing >94% phosphatidylcholine does not appear conclusive. Consuming phosphatidylcholine for 3 months increased the clinical remission rate and improved clinical symptoms compared with placebo. It also reduced the need for steroids, resulting in complete cessation of corticosteroid therapy without disease exacerbation in 80% of patients. Further research in a difficult-to-treat patient group suggests that the effective dose of this slow-release, phosphatidylcholine-rich phospholipid preparation is at least 1 g/day when taken in four divided doses for 12 weeks; however, taking 3 to 4 g per day appears to be more effective. Remission occurred in 50% and 60% of patients taking 3 g or 4 g per day, respectively, compared with 30% of patients taking 1 g per day and 0% of patients taking the control dose of 0.5 grams per day. Moreover, the clinical response in the three treatment groups was 70%, compared with 0% in the control group.

Posologie

posologieOral

posologie10 g


Synergies


Hypercholesterolemia
✪✪✪✪✪

Some clinical research shows that daily intake of 500 mg to 30 g of lecithin for a period of up to 11 months reduces cholesterol levels in healthy people or those diagnosed with hypercholesterolemia. nnHowever, two clinical studies failed to show an effect of lecithin on low-density lipoprotein (LDL) cholesterol or on total cholesterol levels in people with hyperlipidemia.nn

Posologie

posologieOral administration

posologie500 - 30 mg


Properties


Hypocholesterolemic

full-leaffull-leaffull-leafempty-leaf

Phospholipids exert a hypocholesterolemic effect. Thus, in patients suffering from hypercholesterolemia, supplementation with soy lecithin significantly reduces plasma cholesterol levels. In hypercholesterolemic hamsters and rabbits, supplementation with soy phospholipids increases HDL cholesterol levels and reduces the LDL/HDL ratio, which is a known risk factor for metabolic diseases. These effects would be due to the fact that phospholipids are able to decrease microsomal HMG-CoA reductase activity (an enzyme involved in the cholesterol biosynthesis pathway) and enterocytic absorption of cholesterol. They also increase biliary cholesterol excretion, lipid beta-oxidation and plasma ApoA1 concentration (Apolipoprotein A1 is the main protein component of high-density lipoproteins, HDL, which are anti-atherogenic).

Usages associés

Hypercholesterolemia

Metabolic

full-leaffull-leafempty-leafempty-leaf

A study conducted in rats showed that rapeseed lecithin, rich in alpha-linolenic acid (ALA), when added without prior emulsification, was able to induce a dose-dependent increase in the appearance of lipids and ALA in the lymph, which would be associated with an increase in the secretion and size of chylomicrons (lipid particles that transport triglycerides after digestion). As a result, delivery of ALA in the form of phospholipids via rapeseed lecithin would increase its bioavailability, compared with its delivery as triglycerides in an oil. However, the study shows that the beneficial effect of rapeseed lecithin on lipid absorption only becomes significant at supplementation doses (30% of total lipids), much higher than those found in foods, which never exceed 10%. These data validate a dose-dependent effect of plant lecithins on lipid absorption. Regardless of their dose, both lecithins produced changes in the gut microbiota in these mice, increasing the fecal abundance of Clostridium Leptum, a bacterial group described as anti-inflammatory. Rapeseed lecithin would also have a specific effect on bile acid metabolism, promoting the elimination of bile acids, whose accumulation can be toxic. These preclinical data therefore demonstrate that the use of plant lecithins as an ingredient in a balanced diet does not induce any harmful effect on lipid metabolism. Soy and sunflower lecithins would be among the only emulsifiers that do not cause any major deleterious impact on the composition and pro-inflammatory potential of the gut microbiota.

Usages associés

Hypercholesterolemia

Hepatoprotective

full-leafempty-leafempty-leafempty-leaf

Animal research findings suggest that lecithin may protect against alcohol-induced liver damage. Furthermore, the liver plays a central role in lipid metabolism and homeostasis. Several preclinical studies have shown that replacing a fraction of dietary triglycerides with plant lecithins was associated with an improved lipid profile in the liver, with a reduction in hepatic triglycerides.


Neurological

full-leafempty-leafempty-leafempty-leaf

Oral intake of lecithin can increase serum choline levels, which is a precursor of acetylcholine. As a source of choline, lecithin was thought to potentially help alleviate symptoms of cholinergic disorders such as Alzheimer's disease and tardive dyskinesia. However, oral lecithin intake does not appear to affect cholinergic neuronal function.


Anti-inflammatory

full-leafempty-leafempty-leafempty-leaf

Supplementation with phosphatidylcholine produced a significant reduction in the development of arthritis in rats, potentially due to inhibition of the neutrophil-mediated inflammatory response. Soy phosphatidylcholine may limit the inflammatory process in the joints in a chronic murine model of rheumatoid arthritis (collagen-induced arthritis) when administered at disease onset. Pretreatment effectively prevented leukocyte adhesion to the endothelial layer and decreased expression of inducible nitric oxide synthase (iNOS), thereby reducing the degree of synovial angiogenesis. Lecithins, therefore, could prove effective in reducing inflammatory reactions in arthritis and similar inflammatory processes.

Usages associés

Ulcerative colitis


Safe dosage

Adult: 1.5 g - 30 g

Lecithin has been used safely at doses up to 30 grams per day for up to 6 weeks. nn


Precautions

Pregnancy: avoid

There is not enough reliable information on the safety of lecithin at medicinal doses during pregnancy. nn

Breastfeeding: avoid

There is not enough reliable information on the safety of lecithin at medicinal doses during breastfeedingnn

Allergies: use with caution

Lecithin can cause allergic reactions in people who are allergic to eggs or soy.